The oncology toolbox is growing rapidly, with novel treatments or expanded uses being approved almost monthly. Understandably, manufacturers seek to ensure that oncologists are informed of the details for new and existing treatments, and community oncologists generally find product updates to be highly useful. However, an increasingly crowded market is forcing companies to compete for the limited time physicians and practices can allocate for these meetings.
Our 2024 Community Oncology Annual Trend survey examined practices’ points of view toward manufacturers’ digital engagement to identify frustrations arising from current approaches (Figure). HMP Market Access Insight’s (MAI’s) research suggests that manufacturers who engage with providers on their terms are more likely to avoid these causes of frustration.
Figure. Prevalence and Causes of Community Oncology Practices’ Frustrations. (A) Perceived frustrations and inefficiencies with digital manufacturer communications (N = 124 practices). (B) Top three oncology clinic frustrations with manufacturer engagement tactics (N = 113 practices).
Source: HMP Market Access Insights 2024 Community Oncology Annual Trend report.
Key findings include:
We look forward to sharing additional insights later this month when we release our full 2024 Community Oncology Annual Trend report!
Meanwhile, be sure to check out some of our newly available reports and keep an eye out for our other upcoming offerings:
If your organization is interested in learning more about our offerings, please contact Sara Stewart.
As Oncology pathway programs continue to become more prominent in the marketplace, manufacturers are being challenged to assess how influential a specific pathway is.
Daniel BuchenbergerIn the final part of this 3-part podcast series, HMP Executive Vice President Lee Blansett and special guest John Hennessy—health system, provider and oncology strategist—explore emerging models for success in oncology practice economics.
Lee BlansettBispecific antibodies have emerged with great promise, but adoption has been slower than expected. This was a key topic discussed by a panel of 5 experts at the October 2024 Association for Value-Based Cancer Care (AVBCC) conference.
Chris Van Denburg